Trovagene PLK1 inhibitor onvansertib (PCM-075) obtains positive early trial data

today, Trovagene(http:// announcedthat it had obtained positive experimental early data in the treatment of 1b/2 clinicaltrial strial
sin (http://) in patients with metastatic colorectal cancer (CRC) with a second-line therapy in conjunction with Folfiri and Avastin (bevacizumab) in the study of PLK1 inhibitor stakes in theAbout Onvansertib
Onvansertib is a third-generation oral highly selective serine/succulentine-like kinase 1 (PLK1) inhibitor of "first-in-class"PLK1 is a member of the Polo-like kinase family, which is highly expressed in a variety of solid tumors and blood cancers, including breast, prostate, ovarian, lung and rectal cancersPLK1 is considered one of the cornerstones of maintaining normal cell divisionpreclinical trialshave shown that onvansertib and other therapies, such as HDAC inhibitors, can produce synergy effects (synergy) when used in combination with other therapies, which can be used to treat leukemia and multiple solid tumorsonvansertib also treats metastatic resistance prostate cancer (mCRPC) and refractory acute myeloid leukemia (AML) in clinical trialsthe study
the 1b/2 clinical trial was designed to assess the efficacy and safety of patients with metastatic colorectal cancer with a mutation in the KRAS gene as a second-line therapy patients who participated in the trial had received separate treatment from Oropyrimidine and oxaliplatin or were treated in combination with Avastin, but the treatment was poor results showed that a reduction in the load level of tumor KRAS gene mutation was observed in the first batch of patients in the trial through quantitative analysis of circulating tumor DNA (ctDNA) (http://